Immuron (IMRN) Convertible Debt (2017)
Immuron (IMRN) posted Convertible Debt of $173802.7 for Q4 2017, up 2.37% on a QoQ basis from $169773.5 in Q2 2017.
Powered by 
Analysis
Immuron (IMRN) Convertible Debt (2017) Analysis & Trends
Immuron has reported Convertible Debt for 1 years, with the latest figure at $173802.7 in Q4 2017.
- On a quarterly basis, Convertible Debt changed N/A year-over-year to $173802.7 in Q4 2017; TTM through Dec 2017 was $173802.7, a N/A change from a year earlier, with the FY2017 full-year figure at $173271.9, changed N/A from the prior year.
- Convertible Debt was $173802.7 for Q4 2017 at Immuron, up from $169773.5 in the prior quarter.
- The five-year high for Convertible Debt was $173802.7 in Q4 2017, with the low at $169773.5 in Q2 2017.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn |
| 10 | Immuron | 10.28 Mn | 1.26 Mn | - |